Last Updated:
10 Mar 2026, 03:29:50 PM (IST)
Shilpa Medicare Limited
NSE: SHILPAMED BSE: SHILPAMED
NSE
338.65
5.50 (1.65%)
Prev Close
333.15
Open Price
335
Volume
758,443
Today Low / High
333.45 / 345.45
52 WK Low / High
259.5 / 500
Range
322 - 356
BSE
338.95
5.45 (1.63%)
Prev Close
333.5
Open Price
335
Volume
30,163
Today Low / High
334.9 / 345.15
52 WK Low / High
260 / 501.6
Range
322 - 356
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 338.65 (target range: 322 - 356), reflecting a change of 5.5 (1.65091%). On the BSE, it is listed at 338.95 (target range: 322 - 356), showing a change of 5.45 (1.63418%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
315.90
2.42%
27 Feb
338.00
-0.40%
26 Feb
327.45
3.76%
25 Feb
328.00
-0.17%
24 Feb
326.75
-1.90%
23 Feb
324.85
0.58%
20 Feb
328.90
-1.25%
19 Feb
328.80
0.00%
18 Feb
335.00
-1.85%
Shilpa Medicare Limited Graph
Shilpa Medicare Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Shilpa Medicare Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 338.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 338.95 | 342.34 | 308.11 - 376.57 |
| 345.73 | 276.58 - 414.87 | ||
| 349.12 | 244.38 - 453.85 | ||
| Bearish Scenario | 338.95 | 335.56 | 302.00 - 369.12 |
| 332.17 | 265.74 - 398.61 | ||
| 328.78 | 230.15 - 427.42 |
Overview of Shilpa Medicare Limited
ISIN
INE790G01031
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
424,295
Market Cap
63,280,496,567
Last Dividend
0.5
Official Website
IPO Date
2009-12-03
DCF Diff
1,819.55
DCF
-909
Financial Ratios Every Investor Needs
Stock Dividend of SHILPAMED
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-17 | September 17, 25 | 0.5 | 1 | 2025-09-17 | 2025-10-23 | |
| 2022-09-19 | September 19, 22 | 0.55 | 1.1 | 2022-09-20 | 2022-10-28 | |
| 2021-09-20 | September 20, 21 | 0.55 | 1.1 | 2021-09-21 | 2021-10-28 | |
| 2020-03-16 | March 16, 20 | 0.55 | 1.1 | 2020-03-17 | 2020-04-05 | 2020-03-03 |
| 2019-09-12 | September 12, 19 | 0.5 | 1 | 2019-09-13 | 2019-10-20 | 2019-05-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,286.41 Cr | 410.37 Cr | 876.04 Cr | 0.6810 | 48.37 Cr | 294.18 Cr | 204.06 Cr | 78.29 Cr | 4.02 | 310.86 Cr | 0.0609 |
| 2024-03-31 | 1,153.11 Cr | 443.53 Cr | 709.57 Cr | 0.6154 | 30.96 Cr | 299.59 Cr | 376.16 Cr | 31.87 Cr | 1.84 | 245.94 Cr | 0.0276 |
| 2023-03-31 | 1,043.45 Cr | 909.09 Cr | 134.35 Cr | 0.1288 | 49.10 Cr | 29.53 Cr | -9.65 Cr | -32.53 Cr | -1.88 | 113.47 Cr | -0.0312 |
| 2022-03-31 | 1,140.05 Cr | 384.10 Cr | 755.95 Cr | 0.6631 | 55.06 Cr | 55.23 Cr | 125.83 Cr | 60.66 Cr | 3.63 | 223.00 Cr | 0.0532 |
| 2021-03-31 | 900.16 Cr | 270.77 Cr | 629.39 Cr | 0.6992 | 33.81 Cr | 35.72 Cr | 119.30 Cr | 147.78 Cr | 9.07 | 272.63 Cr | 0.1642 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 25.97 Cr | 3,310.71 Cr | 947.01 Cr | 2,372.2364 Cr | 587.75 Cr | 561.78 Cr | 347.93 Cr | 1,674.96 Cr | 0.00 Cr | 0.00 Cr | 40.79 Cr | 674.2322 Cr |
| 2024-03-31 | 30.23 Cr | 3,093.20 Cr | 1,293.25 Cr | 1,808.6941 Cr | 937.39 Cr | 907.16 Cr | 344.93 Cr | 1,638.50 Cr | 0.01 Cr | 15.84 Cr | 39.91 Cr | 693.3482 Cr |
| 2023-03-31 | 21.32 Cr | 2,903.93 Cr | 1,129.57 Cr | 1,783.2770 Cr | 797.89 Cr | 776.57 Cr | 319.82 Cr | 1,537.49 Cr | 0.00 Cr | 17.48 Cr | 52.68 Cr | 784.4477 Cr |
| 2022-03-31 | 33.83 Cr | 2,875.50 Cr | 1,064.35 Cr | 1,822.1948 Cr | 683.29 Cr | 649.46 Cr | 355.24 Cr | 1,491.38 Cr | 25.02 Cr | 19.27 Cr | 45.04 Cr | 611.5362 Cr |
| 2021-03-31 | 122.85 Cr | 2,632.37 Cr | 1,164.87 Cr | 1,478.6666 Cr | 845.93 Cr | 723.09 Cr | 316.84 Cr | 1,330.82 Cr | 7.48 Cr | 17.80 Cr | -21.23 Cr | 603.5029 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 132.1786 Cr | -199.0848 Cr | 62.6537 Cr | -111.4554 Cr | -3.2323 Cr | 28.5237 Cr | -243.6340 Cr | 122.3329 Cr | -349.1709 Cr | 0.0000 Cr | -22.3156 Cr |
| 2024-03-31 | 136.6690 Cr | -166.5844 Cr | 46.7750 Cr | -49.2221 Cr | 12.6846 Cr | 30.4254 Cr | -184.5605 Cr | 31.8742 Cr | 139.6718 Cr | 0.0000 Cr | -25.1071 Cr |
| 2023-03-31 | 179.9236 Cr | -232.6122 Cr | 45.7981 Cr | -46.7438 Cr | -6.5509 Cr | 19.0714 Cr | -226.6674 Cr | -38.2795 Cr | 113.8094 Cr | -9.5482 Cr | 35.4173 Cr |
| 2022-03-31 | 105.1333 Cr | -285.4984 Cr | 82.8583 Cr | -226.6928 Cr | -97.5067 Cr | 25.3391 Cr | -331.8261 Cr | 102.2648 Cr | -163.0498 Cr | -8.9680 Cr | -38.4010 Cr |
| 2021-03-31 | 46.9278 Cr | -404.2761 Cr | 436.3741 Cr | -307.3143 Cr | 79.0259 Cr | 123.3402 Cr | -354.2421 Cr | 195.0519 Cr | 458.6544 Cr | 0.0000 Cr | -106.3432 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 409.73 Cr | 247.14 Cr | 162.58 Cr | 0.3968 | 83.94 Cr | 44.58 Cr | 2.28 | 102.25 Cr | 0.1088 |
| 2025-09-30 | 369.97 Cr | 105.50 Cr | 264.47 Cr | 0.7148 | 78.46 Cr | 44.07 Cr | 2.25 | 109.92 Cr | 0.1191 |
| 2025-06-30 | 321.46 Cr | 79.61 Cr | 241.85 Cr | 0.7524 | 62.72 Cr | 46.89 Cr | 2.40 | 97.28 Cr | 0.1459 |
| 2025-03-31 | 330.79 Cr | 104.47 Cr | 226.32 Cr | 0.6842 | 47.96 Cr | 14.51 Cr | 0.74 | 58.56 Cr | 0.0439 |
| 2024-12-31 | 319.32 Cr | 91.00 Cr | 228.31 Cr | 0.7150 | 51.88 Cr | 31.78 Cr | 1.63 | 81.82 Cr | 0.0995 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 17.95 Cr | 35.60 Cr | 53.55 Cr | 426.88 Cr | 444.87 Cr | 1,058.78 Cr | 1,725.57 Cr | 3,495.11 Cr | 1,056.59 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 28.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,363.70 Cr |
| 2025-03-31 | 25.97 Cr | 32.59 Cr | 58.56 Cr | 440.84 Cr | 347.93 Cr | 985.67 Cr | 1,674.96 Cr | 3,310.71 Cr | 947.01 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 17.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,319.18 Cr |
| 2024-09-30 | 17.01 Cr | 19.51 Cr | 36.52 Cr | 359.83 Cr | 326.55 Cr | 859.04 Cr | 1,623.37 Cr | 3,117.33 Cr | 798.14 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 46.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 14.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 31.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 17.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 14.06 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2025-10-03 | October 03, 25 | 2:1 |
| 2015-11-06 | November 06, 15 | 2:1 |
| 2013-07-16 | July 16, 13 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Operating Officer of Formulations
Jayant Karajgi
Gender: Not Specified
Year Born: 1967
Chief Financial Officer
Alpesh Maheshkumar Dalal
Gender: male
Year Born: 1976
Head of Investor Relations
Monish Shah
Gender: male
Year Born:
Chief Human Resource Officer
V. Narasimha Rao
Gender: male
Year Born:
Vice President of Projects & Operations and Whole-time Director
Sharath Reddy Kalakota M.Pharma
Gender: male
Year Born: 1967
Business Head of Biologics
Vinay Konaje
Gender: male
Year Born: 1973
MD & Director
Vishnukanth Chaturbhuj Bhutada
Gender: male
Year Born: 1962
Chief Scientific Officer of Biologicals
Rajyashri Karur Ramakrishnan
Gender: female
Year Born: 1965
Company Secretary & Compliance Officer
Ritu Tiwary
Gender: female
Year Born: 1977
Senior Vice President of Technical
Pramod Kumar
Gender: Not Specified
Year Born: 1963
FAQs about Shilpa Medicare Limited
Who is the CEO of the company?
The CEO is Vishnukanth Chaturbhuj Bhutada.
What is the current market price of the stock?
The current price is ₹323.55.
What is the 52-week price range?
The range is ₹259.5-500.
What is the market capitalization of the company?
The market capitalization is ₹6,328.05 crores.
What is the dividend yield?
The dividend yield is 0.15%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 42.17.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Shilpa Medicare Limited (ISIN: INE790G01031) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹6,328.05 crores and an average daily volume of 424,295 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.5.